Ranibizumab for Myopic Neovascularization

Sponsor: Instituto de Olhos de Goiania
Study ID: NCT01246089
Phase: PHASE4
Status: Unknown

Conditions

Myopic Choroidal Neovascularization

Eligibility Criteria

Sex: ALL
Age: 21 Years - 65 Years
Healthy Volunteers: Accepted

Interventions

ranibizumab injection — DRUG
Ranibizumab intravitreal injection of 0,5 mg ( 0.05mL)

Study Details

The purpose of this study is to evaluate the clinical results of anti-VEGF intra-vitreal injections (IVT) in CNV secondary to pathologic myopia (PM-CNV).

Key Dates

First listed: Nov 23, 2010
Start date: Jul 31, 2009
Status verified: Dec 2013
Primary completion: Oct 31, 2014
Completion: Nov 30, 2014

Study Design

Enrollment: 20 participants (actual)
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Arms

Experimental: Ranabizumab
Myopic eyes with retinal neovascularization